Cardiology subspecialties: ACHD is lifelong, Loeys–Dietz in pregnancy is an emergency mindset, and cancer survivors need CV rebuild
Panel session from a QCG GP conference — why adult congenital heart disease outnumbers paediatric CHD, how a dilated aortic root in pregnancy forces brutal shared decisions, and what GPs should check in the first year after cancer therapy.
- Panel chair / imaging host
- Dr Vinesh (ASR variants: Venesh / Manish / Vanessa) — advanced echo (Prince Charles) and cardiovascular imaging fellowship (Northwestern, US); cardiac amyloidosis fellowship interest. Frames “newer subspecialties” for GP care.
- ACHD / obstetric cardiology
- Dr Mona Lewin (ASR variants: Mona William / Marlo Lin / Mona Larkin) — adult congenital cardiologist with UK consultant experience (Barts / Southampton); ACHD overview + maternal aortopathy case.
- Cardio-oncology
- Dr Lorcan Ruan (ASR: Walkman/Walken Rowan / Lorcan) — formal cardio-oncology training; GP-relevant risk assessment before/during/after cancer therapy, especially survivorship.
- Mentioned on panel (limited ASR capture)
- Dr Scott McKenzie; Dr Ni Mai (names introduced; substantial later talks not fully captured in this Otter file). CPD logistics: Nicole Larson (Innovating CPD).
- Session context
- Otter id
4o8oKeMzEHhp0mkXt72O9nFHj4U· title Cardiology Subspecialties Conference · ~38.8 min (2329 s) · 2026-02-28. Companion opening: cardiovascular-education-weekend. Otter AI keywords also mention valvular disease / amyloid / cardiac CT — those segments are thin or absent in the exported transcript; blog sticks to spoken ACHD + cardio-oncology content.
Key messages for GPs
- ACHD is a lifelong chronic condition — “repaired” ≠ cured. Residual/new lesions emerge; lifelong cardiology follow-up is the norm.
- Australian registry scale: >70,000 adults with congenital heart disease counted (two states missing; true total likely higher). You are already seeing them for scripts, certificates and unrelated illness.
- Common crash presentations: arrhythmia and endocarditis/sepsis — get them to ACHD-capable urgent care fast.
- Pregnancy + dilated aorta / genetic aortopathy needs pre-pregnancy counselling ideally; once pregnant, decisions are shared, time-critical and multidisciplinary.
- Cancer patients have elevated CV risk before, during and after therapy. Survivorship is where GPs rebuild risk factors, meds and selective echo/biomarkers.
ACHD: more adults than children now
Dr Lewin’s aim was not a catalogue of complex physiology, but context: congenital heart disease is the most common birth defect. Before modern surgery, most children did not reach adulthood. Pioneers (classic story: Robert Gross’s 1939 PDA ligation against institutional caution) plus cardiopulmonary bypass and deep hypothermic arrest flipped survival. By ~2010, adults with CHD outnumbered children with CHD — and the adult cohort keeps growing.
Professor Jane Somerville’s insight ~25 years ago: we needed a specialty for “grown-up congenital heart” (GUCH → now ACHD). Looking after these patients is “much more than cardiology” — psychosocial load of institutionalised childhood care, neurological sequelae, lifestyle questions (sport, travel insurance, career), contraception/genetics, plus acquired atherosclerotic disease as they age.
Risk strata and what unwells them
Broad buckets (details in ESC-style classifications): fully repaired corrective surgery (e.g. some TOF repairs); palliated pathways (shunts, Fontan); newly diagnosed adult lesions (e.g. ASD). ESC framing: CHD is lifelong — new or residual lesions emerge; acute decompensation happens.
- Low(er) risk examples: simple septal defects without major associated disease.
- Moderate: tetralogy of Fallot, transposition pathways, etc.
- High — stay closely involved: cyanotic patients, Fontan, Eisenmenger, systemic RV physiology.
Arrhythmia and endocarditis/sepsis are the two most common paths to critical illness in ACHD. Low threshold for urgent ACHD-capable assessment — do not “trial of oral antibiotics at home” if endocarditis is plausible.
Routine counselling themes Lewin runs: endocarditis education, pregnancy/contraception, lifestyle limits (weightlifting, extreme sports), travel insurance, career choices — “a bit of a life coach” over years of follow-up.
Case: suspected Loeys–Dietz in pregnancy
30-year-old NICU nurse, G2P1, 16 weeks pregnant. Brother died in sleep at 22 — post-mortem aortic dissection. Strong maternal family history of aortopathy / sudden death. Local cardiologist (after GP referral) arranged urgent TOE: structurally normal heart but severely dilated aortic root (~48 mm). Cardiac MRI: isolated root involvement, remainder of aorta and heart normal.
Differential for aortopathy: acquired (atherosclerosis, inflammatory vasculitis) vs congenital syndromes vs genetic aortopathy. Exam with genetics + fetal medicine suggested subtle features of Loeys–Dietz syndrome (aggressive genetic aortopathy; can dissect at near-normal dimensions). Genetics take months — decisions could not wait.
| Option discussed | Framing in the room |
|---|---|
| Continue pregnancy accepting dissection risk | Recommended against — quoted mortality if dissection in pregnancy up to ~70% in this context; aortic dissection is a leading cardiovascular killer in UK pregnancy data. |
| Terminate then urgent aortic surgery | Protects mother; loses pregnancy. |
| Cardiac surgery while pregnant | Patient chose this hoping fetus might survive; cardiopulmonary bypass risk to fetus extremely high for valve-sparing root replacement; PEARS discussed but limited genetic-aortopathy data — patient preferred proven maternal survival strategy. |
Outcome as told: excellent maternal surgical result; pregnancy lost; genetics later confirmed aggressive aortopathy; 2-year-old daughter also affected; cascade screening planned; later successful pre-implantation genetic testing pregnancy with an unaffected child. GP lesson: catch aortopathy before pregnancy when possible; Medicare-supported PGT pathways exist in Australia for eligible genetic conditions.
Cardio-oncology in three chapters
Dr Ruan’s simple definition: care of cardiovascular health in people with a history of cancer. Chronology:
- Before / at diagnosis: risk assessment for proposed treatment.
- During treatment: manage cardiotoxic therapies and CV events.
- After treatment (survivorship): reduce long-term CV risk — the chapter where GPs matter most.
Why the combo specialty? Cancer populations already carry high rates of dyslipidaemia/hypertension and established CVD; shared risk phenotypes (obesity, smoking); cancer is proinflammatory/procoagulant; bidirectional links (e.g. higher cancer rates in heart failure cohorts). During therapy, an Australian registry figure cited: within four years of cancer diagnosis, ~50% had a new cardiovascular diagnosis (many in year one), linked to mortality.
Cardiotoxicity is no longer “just anthracyclines and trastuzumab”. European cardio-oncology guidance was said to list 70+ cancer therapies with CV associations (TKIs, VEGF inhibitors → hypertension; ibrutinib → AF/HF/HTN; immunotherapy → rare but serious myocarditis; myeloma regimens → metabolic and HF effects).
Not “protect the heart at all costs”. Facilitate optimal cancer treatment while minimising clinically significant CV disease during and after therapy — especially so survivors can use the years they gained.
Survivorship: the GP year-one job
Cancer survivors carry ~50% higher CV disease risk vs non-cancer peers in cited data; CV mortality risk can remain elevated for years and may overtake cancer mortality depending on age and cancer type. Drivers include legacy toxicity plus psychosocial neglect of non-cancer health, medication discontinuation, and the oncologist temporarily becoming the “only” doctor.
In the first survivorship year, Ruan’s practical triad: assess risk → consider tests → refer selectively.
- Assess general CV risk (usual absolute-risk factors) in everyone.
- Assess cardio-oncology risk: which cardiotoxic treatments? any CV events during therapy?
- Fill gaps: BP, lipids, glycaemia; consider biomarkers/echo especially after anthracycline, trastuzumab, high cardiac radiation dose, or any cardiotoxic event without a clear follow-up plan.
- Refer cardiology: prior cardiotoxic event; abnormal tests; multiple risk factors / known heart disease; high-dose anthracycline or heart-involving radiation when doses known.
Anyone with a CV event during cancer therapy without follow-up; anyone who received anthracycline or trastuzumab (cumulative dose often unknown to GP — one-off echo screen is reasonable); high baseline CV risk patients; others — thorough risk assessment with low threshold for echo if symptoms/signs.
Clinic checklist
- Tag ACHD patients in the record; note repair/palliation type if known; endocarditis education; do not assume “cured”.
- Pre-pregnancy: any aortopathy, bicuspid aortopathy, Marfan/Loeys–Dietz/family dissection → cardiology + genetics before conception when possible.
- Cancer survivors at 3–12 months: restart/reconcile cardiac meds, BP/lipids/HbA1c, lifestyle, selective echo.
- Know local cardio-oncology and ACHD contacts — these are low-volume/high-stakes referral streams.